Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
URGN 
UroGen Pharma Ltd (URGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: URGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $31.43
1 Year Target Price $31.43
| 5 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.74% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 928.98M USD | Price to earnings Ratio - | 1Y Target Price 31.43 |
Price to earnings Ratio - | 1Y Target Price 31.43 | ||
Volume (30-day avg) 8 | Beta 1.13 | 52 Weeks Range 3.42 - 21.02 | Updated Date 08/15/2025 |
52 Weeks Range 3.42 - 21.02 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.83 | Actual -1.05 |
Profitability
Profit Margin -164.44% | Operating Margin (TTM) -171.17% |
Management Effectiveness
Return on Assets (TTM) -31.2% | Return on Equity (TTM) -1481.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 858042770 | Price to Sales(TTM) 9.86 |
Enterprise Value 858042770 | Price to Sales(TTM) 9.86 | ||
Enterprise Value to Revenue 9.34 | Enterprise Value to EBITDA -2.63 | Shares Outstanding 46264100 | Shares Floating 36858634 |
Shares Outstanding 46264100 | Shares Floating 36858634 | ||
Percent Insiders 6.86 | Percent Institutions 116.1 |
Upturn AI SWOT
UroGen Pharma Ltd
Company Overview
History and Background
UroGen Pharma Ltd. is a biopharmaceutical company founded in 2004. It is focused on developing and commercializing novel solutions for specialty urology and uro-oncology, with the goal of improving treatment options for patients suffering from urological diseases.
Core Business Areas
- Oncology: Development and commercialization of innovative therapeutics for urothelial cancer and other urologic malignancies.
- Urology: Development of solutions for common urological conditions.
Leadership and Structure
The company is led by a board of directors and an executive management team. Key leaders include the CEO, CFO, and Chief Medical Officer. The organizational structure is functional, with departments dedicated to R&D, clinical development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Jelmyto: Jelmyto (mitomycin) is an alkylating agent indicated for the treatment of adult patients with low-grade upper tract urothelial cancer (LG-UTUC). Competitors include traditional surgery, which is invasive, as well as other investigational therapies in clinical development. Revenue is Jelmyto sales, exact market share data is proprietary but it is the first line treatment and a key drug.
Market Dynamics
Industry Overview
The urology and uro-oncology market is growing due to the aging population and increased incidence of urological diseases and cancers. There is a demand for less invasive treatment options and targeted therapies.
Positioning
UroGen Pharma is positioned as a leader in developing non-surgical options for urothelial cancer, particularly LG-UTUC. Its competitive advantage lies in its proprietary technology and first-to-market position with Jelmyto.
Total Addressable Market (TAM)
The TAM for LG-UTUC and other urothelial cancers is estimated to be billions of dollars. UroGen is positioned to capture a significant share of this market with its innovative therapies. Specific estimates depend on market penetration and pricing strategies.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Jelmyto)
- First-to-market advantage in LG-UTUC
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Single product dependency (Jelmyto)
- Limited commercial infrastructure
- Ongoing clinical trial risks
- High operating expenses
Opportunities
- Expansion of Jelmyto label to other indications
- Development of new therapies for other urological conditions
- Partnerships with larger pharmaceutical companies
- Geographic expansion into new markets
Threats
- Competition from other companies developing urothelial cancer therapies
- Regulatory hurdles and delays
- Reimbursement challenges
- Product liability risks
Competitors and Market Share
Key Competitors
- BMY
- MRK
- JNJ
Competitive Landscape
UroGen's main competitive advantage is Jelmyto being the first-to-market non-surgical treatment for LG-UTUC. However, large pharmaceutical companies have greater resources and broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the launch and commercialization of Jelmyto.
Future Projections: Analysts project revenue growth from Jelmyto sales and potential label expansions. Future growth depends on successful pipeline development and commercial execution.
Recent Initiatives: Recent initiatives include ongoing clinical trials, commercialization efforts for Jelmyto, and strategic partnerships.
Summary
UroGen Pharma is positioned as a leader in uro-oncology due to Jelmyto. However, the company depends on a single product and faces competition from larger players. Future growth depends on label expansion and pipeline development, it has a good start in the LG-UTUC market but will face further competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- UroGen Pharma Ltd. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About UroGen Pharma Ltd
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2017-05-04 | President, CEO & Director Ms. Elizabeth A. Barrett | ||
Sector Healthcare | Industry Biotechnology | Full time employees 253 | Website https://www.urogen.com |
Full time employees 253 | Website https://www.urogen.com | ||
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.